Counde Oyang

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.

M. P. Dillon, P. Atadja, Youzhen Wang, 2017, Journal of medicinal chemistry.

Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment

Jiangwei Zhang, Chunye Zhang, M. Walles, 2021, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain

P. Atadja, E. Li, C. Arrowsmith, 2018, SLAS discovery : advancing life sciences R & D.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

P. Atadja, E. Li, Youzhen Wang, 2017, Nature chemical biology.

Absolute quantification of histone PTM marks by MRM-based LC-MS/MS.

P. Atadja, E. Li, R. Sack, 2014, Analytical chemistry.

An allosteric PRC 2 inhibitor targeting the H 3 K 27 me 3 binding pocket of EED

P. Atadja, E. Li, Youzhen Wang, 2016 .

Quantitative Profiling of Combinational K27/K36 Modifications on Histone H3 Variants in Mouse Organs.

E. Li, Pengyuan Yang, Shaolian Zhou, 2016, Journal of proteome research.